On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

Tekmira’s Lipid Nanoparticle (LNP) Technology Targeting Ebola Like Virus Highlighted in Scientific Publication

Data From Animal Model Demonstrates Complete Protection Three Days After Infection August 20th, 2014 Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira’s lipid nanoparticle (LNP) technology. Tekmira, along with …